<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01602900</url>
  </required_header>
  <id_info>
    <org_study_id>116038</org_study_id>
    <nct_id>NCT01602900</nct_id>
  </id_info>
  <brief_title>Healthy Volunteer Positron Emission Tomography (PET) Brain Occupancy Study of a Phosphodiesterase 4 (PDE4) Inhibitor in Huntington's Disease</brief_title>
  <official_title>An Open Label Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain PDE4 Engagement, Pharmacokinetics and Safety of Single Oral Doses of GSK356278, Using 11C-(R)-Rolipram as a PET Ligand(s)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate if a new experimental drug to treat Huntington's Disease gets
      into the brain. If it does get into the brain the study will explore the relationship between
      the amount of drug in the brain and the amount of drug in the blood. The study will involve
      healthy male volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label, non-randomized, adaptive design PET occupancy study in healthy adult
      males. The primary aim of this study is to describe the relationship between plasma
      concentrations and brain PDE4 occupancy of GSK356278 over time. Up to 24 healthy volunteers
      may be administered single doses of GSK356278 in order to obtain 12 evaluable complete data
      sets of occupancy estimates. This study will help to optimize the dose selection for future
      clinical studies with GSK356278.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 22, 2011</start_date>
  <completion_date type="Actual">April 12, 2012</completion_date>
  <primary_completion_date type="Actual">April 12, 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positron Gamma-ray emmision &amp; voxel counts</measure>
    <time_frame>60 minutes</time_frame>
    <description>Brain regions of interest and associated radionuclitide-activity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>systemic plasma concentration</measure>
    <time_frame>24 hours</time_frame>
    <description>serial sampling: GSK356278 concentration expressed as mass per unit of volume</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood pressure - mm/Hg</measure>
    <time_frame>24 hours</time_frame>
    <description>Standard clinical pharmacology safety monitoring of vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG - 12-Lead &amp; Telemetry</measure>
    <time_frame>24 &amp; 72 hours</time_frame>
    <description>Standard clinical pharmacology safety monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate - bpm</measure>
    <time_frame>72 hours</time_frame>
    <description>Standard clinical pharmacology safety monitoring of vital signs</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Huntington Disease</condition>
  <arm_group>
    <arm_group_label>GSK356278</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK356278</intervention_name>
    <description>Investigational Medicinal Product</description>
    <arm_group_label>GSK356278</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rolipram</intervention_name>
    <description>Challenge Agent</description>
    <arm_group_label>GSK356278</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male volunteer, aged 22-55 years.

          -  Normal blood pressure, laboratory values, and body mass index

          -  Willing to agree to study procedures &amp; contraception requirements

          -  Capable of giving written informed consent

        Exclusion Criteria:

          -  Any evidence of disease that would preclude participation in the clinical study
             (includes sexually transmitted diseases, exessive alcohol consumption, and substance
             abuse).

          -  Previously involved in another clinical trial within 3 months prior to scheduled
             administration of study drug

          -  Smoker

          -  Suffers from claustrophobia

          -  Any contraindications for MRI scanning (e.g. pacemaker, metal implants or fillings)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>NW10 7EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>W12 ONN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <link>
    <url>https://www.gsk-clinicalstudyregister.com/study/116038?search=study&amp;search_terms=116038#rs</url>
    <description>Results for study 116038 can be found on the GSK Clinical Study Register.</description>
  </link>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2011</study_first_submitted>
  <study_first_submitted_qc>May 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2012</study_first_posted>
  <last_update_submitted>June 19, 2017</last_update_submitted>
  <last_update_submitted_qc>June 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Huntington Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rolipram</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>116038</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116038</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116038</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116038</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116038</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116038</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116038</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

